tscan.com (TCRX) Forward P/S Multiple
TScan Therapeutics (TCRX) forward P/S dynamics correlate with its progress in developing personalized cell therapies and overall market confidence in the biotech sector. Patent protection and costly R&D create a high barrier to entry. The manufacturing base in Massachusetts relies on autonomous bioreactors and redundant IT systems. This chart analysis helps avoid overpaying for the asset, while 1.50 serves as the final level marker.
Comprehensive metric breakdowns and analytics for tscan.com (TCRX)
- market price and analyst price targets:
- market capitalization details:
- issuer book value statistics:
- debt level and financial liquidity data:
Total Debt to Equity Ratio TScan Therapeutics|TCRX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio TScan Therapeutics, Inc.|TCRX - Company Cumulative Indebtedness|Debts to Book Capitalization TCRX|TCRX - Company Long-Term Loans and Borrowings|Company Short-Term Debts TScan Therapeutics|Quick Liquidity tscan.com
- financial results and valuation multiples details:
TCRX - Final Profit|Projected Future Earnings TScan Therapeutics|TCRX - P/E Multiple|Future Price to Earnings TScan Therapeutics, Inc.|TCRX - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple TCRX|TCRX - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months TScan Therapeutics|TCRX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months tscan.com|TCRX - Net earnings per one share growth for the current year|Earnings growth forecast for next year TScan Therapeutics
- total revenue and sales volume data:
General company analysis:TScan TCRX
This indicator measures market expectations by comparing current capitalization with projected revenue to determine the asset's degree of overvaluation during periods of volatility. By analyzing the projected price-to-sales ratio, an investor can assess the impact of FDA regulatory restrictions on the scaling rates of TScan Therapeutics (TCRX) T-cell therapy, balancing the growth potential of the oncology ecosystem against the risk of capital stagnation.
Key competitors
Price-to-Projected Revenue Ratio BeiGene ONC|Market Cap to Expected Sales Ratio Halozyme Therapeutics, Inc. (HALO)|RevMed - Forward P/S Multiple|Ascentage Pharma Corp (AAPG) - Forward Price-to-Revenue Multiple|CGON: Forward P/S Multiple|urogen.com (URGN) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Bicara Therapeutics|Market Cap to Projected Revenue PSNL (Personalis Inc)|Forward Price-to-Revenue Multiple ERAS (Erasca Corp)|DCTH (Delcath Corp) - Forward Price to Sales|Y-mAbs Therapeutics - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio AURA (aurabiosciences.com)|Candel - Forward P/S Multiple|Forward Price to Sales ARAY (Accuray Inc)|SLS: Forward P/S Multiple|Market Cap to Future Revenue Ratio Actuate Therapeutics Inc (ACTU)|Price-to-Projected Revenue Ratio Citius Oncology, Inc.|HURA: Forward Price to Sales|Forward P/S Multiple TARA|Forward P/S Multiple Fate Therapeutics Inc (FATE)|Price-to-Projected Revenue Ratio Aadi Bioscience WHWK|CSBR (Champions Oncology Inc) - Future Price to Revenue|XBiotech USA - Forward P/S Multiple|Market Cap to Future Revenue Ratio CEL-SCI Corporation|OSTX (OS Therapies) - Forward Price-to-Revenue Multiple|radiopharmtheranostics.com (RADX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple ARTV|ANL (Adlai Nortye Limited) - Price to Expected Revenue Ratio|Forward P/S Multiple VERU|Market Cap to Expected Sales Ratio tempesttx.com|Forward P/S Multiple XLO (Xilio Therapeutics)|RENB - Forward Price-to-Revenue Multiple|MURA - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Kairos Pharma Ltd KAPA|OKUR (onkuretherapeutics.com) - Forward Price-to-Revenue Multiple|GDTC: Price to Expected Revenue Ratio|CRIS (Curis Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Apollomics Corp (APLM)|Price-to-Projected Revenue Ratio Tharimmune Corp (THAR)|ADVB (advanbiomed.com) - Forward Price to Sales|Genprex, Inc. - Forward Price-to-Revenue Multiple|CLDI: Market Cap to Projected Revenue|Sunshine Biopharma, Inc. - Forward P/S Multiple|Xenetic Biosciences (XBIO) - Forward Price-to-Revenue Multiple|SLRX: Forward P/S Multiple|Kitov Pharma (PPBT) - Forward P/S Multiple|Price-to-Projected Revenue Ratio American Oncology Network Inc|Market Cap to Projected Revenue BGNE (beigene.com)|Forward P/S Multiple CKPT|Forward Price-to-Revenue Multiple elevationoncology.com ELEV|Forward P/S Multiple ICAD (iCAD)|Ikena Oncology Inc. (IKNA) - Market Cap to Future Revenue Ratio|NTBL - Price-to-Projected Revenue Ratio|Forward Price to Sales VIRX (Viracta Therapeutics)|MOR (MorphoSys) - Forward Price-to-Revenue Multiple|NAYA Biosciences Inc - Forward Price to Sales|AAPGV (Ascentage Pharma Group Ltd) - Forward P/S Multiple
